{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T13:38:22Z","timestamp":1794577102023,"version":"4.9.1"},"reference-count":27,"publisher":"Informa UK Limited","issue":"7","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Sun Pharmaceutical Industries, Inc"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Journal of Dermatological Treatment"],"published-print":{"date-parts":[[2021,10,3]]},"DOI":"10.1080\/09546634.2019.1698700","type":"journal-article","created":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T07:09:54Z","timestamp":1585724994000},"page":"693-700","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":10,"title":["Comparative cost-effectiveness of tildrakizumab and other commonly used treatments for moderate-to-severe psoriasis"],"prefix":"10.1080","volume":"32","author":[{"given":"Jashin J.","family":"Wu","sequence":"first","affiliation":[{"name":"Dermatology Research and Education Foundation","place":["Irvine, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Jia","sequence":"additional","affiliation":[{"name":"RTI Health Solutions","place":["Manchester, UK"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhao","sequence":"additional","affiliation":[{"name":"Sun Pharmaceutical Industries","place":["Princeton, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Carrico","sequence":"additional","affiliation":[{"name":"RTI Health Solutions","place":["Research Triangle Park, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thor-Henrik","family":"Brodtkorb","sequence":"additional","affiliation":[{"name":"RTI Health Solutions","place":["Ljungskile, Sweden"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Mendelsohn","sequence":"additional","affiliation":[{"name":"Sun Pharmaceutical Industries","place":["Princeton, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Lowry","sequence":"additional","affiliation":[{"name":"Sun Pharmaceutical Industries","place":["Princeton, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0090-6289","authenticated-orcid":false,"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[{"name":"Wake Forest School of Medicine","place":["Winston-Salem, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"April","family":"Armstrong","sequence":"additional","affiliation":[{"name":"Southern California Clinical and Translational Science Institute","place":["Los Angeles, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2020,4]]},"reference":[{"key":"e_1_3_4_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2013.11.013"},{"issue":"4","key":"e_1_3_4_3_1","first-page":"636","article-title":"Chronic plaque psoriasis","volume":"73","author":"Luba KM","year":"2006","unstructured":"Luba KM, Stulberg DL. Chronic plaque psoriasis. Am Fam Physician. 2006;73(4):636\u2013644.","journal-title":"Am Fam Physician"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13555-016-0153-2"},{"issue":"8","key":"e_1_3_4_5_1","first-page":"843","article-title":"Increased prevalence of psychiatric disorders and health care-associated costs among patients with moderate-to-severe psoriasis","volume":"10","author":"Han C","year":"2011","unstructured":"Han C, Lofland JH, Zhao N, et\u00a0al. Increased prevalence of psychiatric disorders and health care-associated costs among patients with moderate-to-severe psoriasis. J Drugs Dermatol. 2011;10(8):843\u2013850.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2017.10.012"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.2147\/PPA.S39887"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.5070\/D32110028943"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1185\/03007990903185557"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2015.06.049"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40268-016-0152-x"},{"key":"e_1_3_4_12_1","unstructured":"Institute for Clinical and Economic Review. Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: condition update. Final Evidence Report. 2018. [cited 2018 Sep 10]. Available from: https:\/\/icer-review.org\/wp-content\/uploads\/2017\/11\/ICER_Psoriasis_Update_Final_Evidence_Report_080118.pdf."},{"key":"e_1_3_4_13_1","unstructured":"Institute for Clinical and Economic Review. Targeted immunomodulators for the treatment of moderate-to-severe plaque psoriasis: effectiveness and value. Final Evidence Report. 2016. [cited 2017 Jul 22]. Available from: https:\/\/icer-review.org\/wp-content\/uploads\/2016\/11\/NE_CEPAC_Psoriasis_Evidence_Report_FINAL_012317.pdf."},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2018.24.12.1210"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2018.1466022"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.18553\/jmcp.2015.21.3.201"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.13343"},{"issue":"3","key":"e_1_3_4_18_1","first-page":"1","article-title":"United States Life Tables, 2013","volume":"66","author":"Arias E","year":"2017","unstructured":"Arias E, Heron M, Xu J. United States Life Tables, 2013. Natl Vital Stat Rep. 2017;66(3):1\u201364.","journal-title":"Natl Vital Stat Rep"},{"key":"e_1_3_4_19_1","unstructured":"Micromedex: Thomson Reuters. Red Book Online. [cited 2019\u00a0May 14]. Available from: http:\/\/www.micromedexsolutions.com."},{"key":"e_1_3_4_20_1","unstructured":"Celgene Corporation. Apremilast (Otezla) prescribing information. 2017. [cited 2017 Jul 26]. Available from: https:\/\/www.celgene.com\/content\/uploads\/otezla-pi.pdf."},{"key":"e_1_3_4_21_1","unstructured":"Janssen Biotech. Guselkumab (Tremfya) prescribing information. 2017. [cited 2017 Jul 26]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761061s000lbl.pdf."},{"key":"e_1_3_4_22_1","unstructured":"Valeant Pharmaceuticals North America LLC. SILIQ (brodalumab) prescribing information. 2017. [cited 2017 Jul 26]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/761032lbl.pdf."},{"key":"e_1_3_4_23_1","unstructured":"Eli Lilly and Company. Ixekizumab (Taltz) prescribing information. 2017. [cited 2017 Jul 26]. Available from: https:\/\/pi.lilly.com\/us\/taltz-uspi.pdf."},{"key":"e_1_3_4_24_1","unstructured":"Novartis Pharmaceuticals Corporation. Secukinumab (Cosentyx) prescribing information. 2017. [cited 2017 Jul 26]. Available from: https:\/\/www.pharma.us.novartis.com\/sites\/www.pharma.us.novartis.com\/files\/cosentyx.pdf."},{"key":"e_1_3_4_25_1","unstructured":"UBC Inc. Certolizumab pegol (Cimzia) prescribing information. 2017. [cited 2017 Jul 26]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/125160s270lbl.pdf."},{"key":"e_1_3_4_26_1","unstructured":"Centers for Medicare and Medicaid Services. Physician fee schedule. 2017. [cited 2017 Sep 25]. Available from: https:\/\/www.cms.gov\/apps\/physician-fee-schedule\/."},{"key":"e_1_3_4_27_1","unstructured":"National Institute for Health and Care Excellence. Single technology appraisal. Secukinumab for treating moderate to severe plaque psoriasis [TA350]. 2015. [cited 2017 Jul 27]. Available from: https:\/\/www.nice.org.uk\/guidance\/ta350."},{"key":"e_1_3_4_28_1","unstructured":"Center for Medicare and Medicaid Services. National and State Summaries of Inpatient Charge Data FY2015. 2017. [cited 2017 Oct 3]. Available from: https:\/\/www.cms.gov\/Research-Statistics-Data-and-Systems\/Statistics-Trends-and-Reports\/Medicare-Provider-Charge-Data\/Inpatient2015.html."}],"container-title":["Journal of Dermatological Treatment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/09546634.2019.1698700","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T18:05:35Z","timestamp":1770401135000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/09546634.2019.1698700"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":27,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2021,10,3]]}},"alternative-id":["10.1080\/09546634.2019.1698700"],"URL":"https:\/\/doi.org\/10.1080\/09546634.2019.1698700","relation":{},"ISSN":["0954-6634","1471-1753"],"issn-type":[{"value":"0954-6634","type":"print"},{"value":"1471-1753","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijdt20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ijdt20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2019-11-11","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2019-11-21","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2020-04-01","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}